MedPageToday -- Patients with advanced breast cancer had a fourfold greater risk of congestive heart failure (CHF) when treated with bevacizumab (Avastin) compared with control or placebo treatment, although the overall risk of CHF was low, according to a meta-analysis involving almost 3,800 patients.
